VentriPoint DiagnosticsVPTDF -4.66%10 3-Year ROIIC % is 65.35 as of Dec. 2025. GuruFocus rates VPTDF with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 799 Medical Devices & Instruments companies, VentriPoint Diagnostics ranks better than 85.11% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
VentriPoint Diagnostics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 65.35%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for VentriPoint Diagnostics's 3-Year ROIIC % or its related term are showing as below:
VPTDF's 3-Year ROIIC % is ranked better than 85.11% of 799
companies
in the Medical Devices & Instruments industry
Industry Median: 1.78
vs VPTDF: 65.35
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
VentriPoint Diagnostics 3-Year ROIIC % Related Terms
VentriPoint Diagnostics 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, VentriPoint Diagnostics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VentriPoint Diagnostics 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where VentriPoint Diagnostics's 3-Year ROIIC % falls into.
VentriPoint Diagnostics's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -2.4253135 (Dec. 2025) - -3.536 (Dec. 2022) )
/
( 1.91 (Dec. 2025) - 0.298 (Dec. 2022) )
=
1.1106865
/
1.612
=
68.90%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
VentriPoint Diagnostics (VPTDF) has a 3-Year ROIIC % of 65.35 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on VentriPoint Diagnostics and its competitors. According to the industry distribution chart, VentriPoint Diagnostics ranks #119 out of 799 companies in the Medical Devices & Instruments industry, placing it in the top 14.9%.
Is VentriPoint Diagnostics' 3-Year ROIIC % too high?
VentriPoint Diagnostics' current 3-Year ROIIC % is 65.35. The Medical Devices & Instruments industry median 3-Year ROIIC % is 1.78. VentriPoint Diagnostics' value of 65.35 is 3571.3% above this industry median. Based on the distribution chart, VentriPoint Diagnostics ranks #119 out of 799 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, VentriPoint Diagnostics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does VentriPoint Diagnostics' 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VentriPoint Diagnostics ranks #119 out of 799 companies for 3-Year ROIIC %. This places VentriPoint Diagnostics in the top 15% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 1.78. VentriPoint Diagnostics' value of 65.35 is 3571.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.78, based on 799 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VentriPoint Diagnostics's current 3-Year ROIIC % of 65.35 is 3571.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on VentriPoint Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VentriPoint Diagnostics's current 3-Year ROIIC % is 65.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current 3-Year ROIIC % of 65.35. The current 3-Year ROIIC % is 65.35 and 3571.3% above the Medical Devices & Instruments industry median of 1.78. VentriPoint Diagnostics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current 3-Year ROIIC % is 65.35 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
10GF Score
Get the complete analysis for VPTDF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VPTDF has been successfully added to your 
